The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Levonantradol     [(6S,6aR,9R,10aR)-9-hydroxy- 6-methyl-3...

Synonyms: l-Nantradol, AC1NSFIT, SureCN119722, LS-176867, PDSP2_000184, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of l-Nantradol


Psychiatry related information on l-Nantradol


High impact information on l-Nantradol


Chemical compound and disease context of l-Nantradol


Biological context of l-Nantradol


Anatomical context of l-Nantradol


Associations of l-Nantradol with other chemical compounds


Gene context of l-Nantradol

  • Levonantradol, a synthetic cannabinoid analog, also increased adenylate cyclase activity while its optical isomer dextronantradol did not [20].
  • While no totally noncannabimimetic agents with potent analgesic effects have yet been identified among derivatives of THC, selectivity has been uncovered for levonantradol, HHC (racemic-9-nor, 9-beta-OH-hexahydrocannabinol) and several structurally related compounds [21].

Analytical, diagnostic and therapeutic context of l-Nantradol

  • We have recently described a potent, cannabinoid-related analgetic, levonantradol, which acts stereospecifically in animals to produce analgesia qualitatively similar to morphine but at 1/9 to 1/34 the dose [16].
  • We report here our initial observations with the antiemetic levonantradol in 12 patients with advanced solid tumors receiving cytotoxic polychemotherapy [22].
  • The pharmacokinetic behavior of levonantradol, administered orally or intramuscularly, has been investigated in man at dose levels of 0.25 to 3.0 mg and in animals at 0.03 to 10 mg/kg, using a specific HPLC/electrochemical assay [12].
  • Levonantradol for chemotherapy-induced emesis: phase I-II oral administration [23].


  1. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Darmani, N.A. Neuropsychopharmacology (2001) [Pubmed]
  2. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Meschler, J.P., Howlett, A.C., Madras, B.K. Psychopharmacology (Berl.) (2001) [Pubmed]
  3. Dose ranging evaluation of the antiemetic efficacy and toxicity of intramuscular levonantradol in cancer subjects with chemotherapy-induced emesis. Stambaugh, J.E., McAdams, J., Vreeland, F. Journal of clinical pharmacology. (1984) [Pubmed]
  4. Evaluation of intramuscular levonantradol and placebo in acute postoperative pain. Jain, A.K., Ryan, J.R., McMahon, F.G., Smith, G. Journal of clinical pharmacology. (1981) [Pubmed]
  5. The effects of levonantradol hydrochloride on tumor growth and therapy. Wolff, J.S., Hemsworth, G.R., DeMaio, M., Sloan, D. Journal of clinical pharmacology. (1981) [Pubmed]
  6. Behaviroal, pharmacological, and molecular characterization of an amphibian cannabinoid receptor. Soderstrom, K., Leid, M., Moore, F.L., Murray, T.F. J. Neurochem. (2000) [Pubmed]
  7. D(2), but not D(1) dopamine receptor agonists potentiate cannabinoid-induced sedation in nonhuman primates. Meschler, J.P., Clarkson, F.A., Mathews, P.J., Howlett, A.C., Madras, B.K. J. Pharmacol. Exp. Ther. (2000) [Pubmed]
  8. Effects of single and repeated daily injections of morphine, clonidine and l-nantradol on responding of squirrel monkeys under escape titration. Smith, J.B. J. Pharmacol. Exp. Ther. (1985) [Pubmed]
  9. Electric shock titration in squirrel monkeys following administration of nantradol, levonantradol, or N-methyl levonantradol. Dykstra, L.A. Psychopharmacology (Berl.) (1983) [Pubmed]
  10. Behavioral effects of levonantradol and nantradol in the rhesus monkey. Young, A.M., Katz, J.L., Woods, J.H. Journal of clinical pharmacology. (1981) [Pubmed]
  11. Double-blind multiple-dose crossover study of the antiemetic effect of intramuscular levonantradol compared to prochlorperazine. Sheidler, V.R., Ettinger, D.S., Diasio, R.B., Enterline, J.P., Brown, M.D. Journal of clinical pharmacology. (1984) [Pubmed]
  12. Pharmacokinetics of levonantradol in laboratory animals and man. Shepard, R.M. Journal of clinical pharmacology. (1981) [Pubmed]
  13. Phase 1 trial of levonantradol in chemotherapy-induced emesis. Tyson, L.B., Gralla, R.J., Clark, R.A., Kris, M.G., Bordin, L.A., Bosl, G.J. Am. J. Clin. Oncol. (1985) [Pubmed]
  14. Facilitation of benzodiazepine binding by levonantradol. Koe, B.K., Weissman, A. Journal of clinical pharmacology. (1981) [Pubmed]
  15. Levonantradol-induced inhibition of acetylcholine turnover in rat hippocampus and striatum. Costa, E., Cheney, D.L., Murray, T.F. Journal of clinical pharmacology. (1981) [Pubmed]
  16. Levonantradol: a role for central prostanoid mechanisms? Milne, G.M., Johnson, M.R. Journal of clinical pharmacology. (1981) [Pubmed]
  17. Effects of morphine, levonantradol, and N-methyllevonantradol on shock intensity discrimination. Dykstra, L.A. Journal of clinical pharmacology. (1981) [Pubmed]
  18. Randomized crossover study of the antiemetic activity of levonantradol and metoclopramide in cancer patients receiving chemotherapy. Heim, M.E., Queisser, W., Altenburg, H.P. Cancer Chemother. Pharmacol. (1984) [Pubmed]
  19. Randomised clinical trial of levonantradol and chlorpromazine in the prevention of radiotherapy-induced vomiting. Lucraft, H.H., Palmer, M.K. Clinical radiology. (1982) [Pubmed]
  20. Possible role of prostaglandins in the effects of the cannabinoids on adenylate cyclase activity. Hillard, C.J., Bloom, A.S. Eur. J. Pharmacol. (1983) [Pubmed]
  21. On the definition of cannabinoids: botanical? chemical? pharmacological? Weissman, A. Journal of clinical pharmacology. (1981) [Pubmed]
  22. Clinical experience with levonantradol hydrochloride in the prevention of cancer chemotherapy-induced nausea and vomiting. Heim, M.E., Romer, W., Queisser, W. Journal of clinical pharmacology. (1981) [Pubmed]
  23. Levonantradol for chemotherapy-induced emesis: phase I-II oral administration. Laszlo, J., Lucas, V.S., Hanson, D.C., Cronin, C.M., Sallan, S.E. Journal of clinical pharmacology. (1981) [Pubmed]
WikiGenes - Universities